30-Second Takeaway
- Four-week oral vancomycin taper after initial CDI therapy delays early recurrence with similar safety but modest overall benefit.
- Molecular respiratory POCT and TAC platforms broaden etiologic diagnosis yet rarely change adult antibiotic use or hard outcomes.
- EHR-derived colonization pressure and advanced NGS assays offer actionable infection-control and pulmonary diagnostic gains.
Week ending February 28, 2026
Diagnostics and therapeutics in transition: CDI vancomycin tapering, molecular testing limits, and hidden respiratory and TB burdens
Four-week vancomycin taper modestly reduces early CDI recurrence versus two-week pulse
Adults with first or first-recurrent CDI who improved by day 10 received a standardized two-week oral vancomycin pulse, then were randomized. Adding a four-week taper reduced recurrence by day 38 (6.7% vs 15.4%; adjusted RR 0.43, 95% CrI 0.19-0.89; superiority probability 99%). By day 56, recurrence remained numerically lower (14.8% vs 17.7%; adjusted RR 0.84, 95% CrI 0.48-1.45) with a 73.8% superiority probability. Adverse events were rare and similar, suggesting good tolerability of the extended regimen. This accessible taper strategy may help delay or modestly reduce early recurrence when fidaxomicin, bezlotoxumab, or FMT are not used.
Molecular respiratory POCT rarely reduces antibiotic use or hard outcomes in adult ARTIs
This meta-analysis of 25 RCTs (12,638 patients) evaluated molecular POCT for acute respiratory tract infections. Overall, mPOCT minimally affected antibiotic use (RR 0.95, 95% CI 0.90-1.00) and treatment duration (mean difference -0.44 days). In adults, high-certainty evidence showed no change in antibiotic use (RR 1.00, 95% CI 0.98-1.02), while pediatric data suggested possible reduction with low certainty. mPOCT doubled appropriate antibiotic prescribing (RR 2.07, 95% CI 1.55-2.77) but did not change 30-day mortality or ICU admission. These data argue against routine mPOCT in adults solely to curb antibiotic exposure or improve major outcomes.
EHR-derived colonization pressure robustly predicts nosocomial pathogen acquisition
Investigators used EHR data from a large US integrated health system to build an open-source tool calculating real-time ward-level colonization pressure. Higher colonization pressure for a given organism consistently increased nosocomial acquisition risk for that organism, independent of resistance phenotype. They also observed positive associations between disparate organisms and negative associations between pathogens occupying distinct niches. Results indicate substantial ongoing nosocomial transmission despite advanced infection control programs. The publicly released software and patient-level dataset enable infection-prevention teams to implement colonization-pressure surveillance and target interventions.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.